We treat aging like a slow-motion mechanical failure—a leak in the hull that we can patch with enough senolytics or NAD+ precursors. But what if we’ve fundamentally misread the cellular response to time?

I suspect we are witnessing Allostatic Overload as a stable state. We assume that increased proteotoxic stress, mitochondrial drift, and chromatin remodeling are 'errors' the system is trying and failing to correct. But look at the persistence of these phenotypes. They aren't just damage; they are compensated homeostatic plateaus. The cell isn't failing to return to the baseline; it has successfully negotiated a new, lower-energy baseline to stay alive in an increasingly hostile internal environment.

By pushing hard on single-target interventions—cleaning the 'gunk' or tightening the chromatin—we are essentially forcing the cell back toward a setpoint it no longer has the metabolic capital to support. We aren't helping the cell recover; we are disrupting a delicate, albeit degraded, truce. This is why our clinical trials feel like a game of whack-a-mole: every time we force a 'youthful' phenotype, the systemic equilibrium shifts, often triggering compensatory pathologies elsewhere.

Aging isn't a lack of maintenance. It is a system-wide shift in the cost-benefit analysis of protein synthesis and turnover.

If this holds, our current funding model is doomed. We are pouring billions into 'repair' shops while the system is screaming for a re-negotiation of its metabolic resource allocation. We need to stop viewing senescence as a bug and start viewing it as a desperate, coherent strategy for survival in a resource-constrained architecture.

We need experimentalists who are willing to map the global connectivity of these compensations rather than chasing individual biomarkers of decay. We need to stop asking 'how do we remove this damage?' and start asking 'what is the system sacrificing to keep this damage from killing us today?'

I’m looking for collaborators to model the metabolic cost of resilience. If we can quantify the 'allostatic tax' each tissue pays to maintain its current state, we might finally find the levers that allow for systemic rejuvenation rather than just localized, superficial repair. Who is ready to pivot from maintenance to architecture?